fisher300
Member
- Awards
- 0
MuscleMeds Claims Reviewed
The National Advertising Review Council (NARC), part of the Council of Better Business Bureaus’ National Advertising Division (NAD) recommended Little Falls, NJ-based MuscleMeds Performance Technologies (sister company of both MHP and Xero Limits) modify or discontinue certain advertising claims for its Methyl Arimatest dietary supplement product.
Claims Reviewed
NAD examined certain claims for the two-part dietary supplement, including increasing (“skyrocket”) testosterone levels, “clinically tested” claims and a “breakthrough” mechanism of action.
What’s Inside The Box?
Packaged in a single box are two formulas with different dosing instructions and ingredients; Formula 1 is a dihydrotase complex and Formula 2 contains methylated flavones.During the NAD review, MuscleMeds did supply requested substantiation.
Increase Testosterone By Over 10,000 pg/mL
Regarding the clinical testing and amount of testosterone increase (“over 10,000 pg/mL”), the advertiser relied on a 2008 clinical study on Formula 1, sold under the trade name Mytosterone. The ingredient is a proprietary blend of saw palmetto and astaxanthin, sold by Triarco Industries, and the study did find statistically significant increases in testosterone in users. However, cited studies for Formula 2 were conducted in vitro or in animals, which NAD determined could not be used to substantiate the claims made for use in humans. Further, claims regarding synergism between the products were found to be unsubstantiated.
Clinically Tested
The 2008 clinical study was found to be adequate substantiation for the claim about the product being “clinically tested,” as long as the claim is limited to the Formula 1 component. Also, the claim on the mechanism of action was correct per the study findings. However, NAD recommended MuscleMeds discontinue its “skyrocketing” testosterone claim and “greatest breakthrough in testosterone supplementation history” claim.
In an advertiser’s statement, MuscleMeds said it would take the NAD recommendations into consideration when developing future marketing, adding, “MuscleMeds appreciates NAD’s fair and balanced review process and continues to support the NAD’s advertising self-regulation program.”
SOURCE: Natural Products Insider
The National Advertising Review Council (NARC), part of the Council of Better Business Bureaus’ National Advertising Division (NAD) recommended Little Falls, NJ-based MuscleMeds Performance Technologies (sister company of both MHP and Xero Limits) modify or discontinue certain advertising claims for its Methyl Arimatest dietary supplement product.
Claims Reviewed
NAD examined certain claims for the two-part dietary supplement, including increasing (“skyrocket”) testosterone levels, “clinically tested” claims and a “breakthrough” mechanism of action.
What’s Inside The Box?
Packaged in a single box are two formulas with different dosing instructions and ingredients; Formula 1 is a dihydrotase complex and Formula 2 contains methylated flavones.During the NAD review, MuscleMeds did supply requested substantiation.
Increase Testosterone By Over 10,000 pg/mL
Regarding the clinical testing and amount of testosterone increase (“over 10,000 pg/mL”), the advertiser relied on a 2008 clinical study on Formula 1, sold under the trade name Mytosterone. The ingredient is a proprietary blend of saw palmetto and astaxanthin, sold by Triarco Industries, and the study did find statistically significant increases in testosterone in users. However, cited studies for Formula 2 were conducted in vitro or in animals, which NAD determined could not be used to substantiate the claims made for use in humans. Further, claims regarding synergism between the products were found to be unsubstantiated.
Clinically Tested
The 2008 clinical study was found to be adequate substantiation for the claim about the product being “clinically tested,” as long as the claim is limited to the Formula 1 component. Also, the claim on the mechanism of action was correct per the study findings. However, NAD recommended MuscleMeds discontinue its “skyrocketing” testosterone claim and “greatest breakthrough in testosterone supplementation history” claim.
In an advertiser’s statement, MuscleMeds said it would take the NAD recommendations into consideration when developing future marketing, adding, “MuscleMeds appreciates NAD’s fair and balanced review process and continues to support the NAD’s advertising self-regulation program.”
SOURCE: Natural Products Insider
